Unlike dynamic analysis techniques, SAST operates without executing the program, focusing entirely on the static codebase.
Vir Biotechnology (VIR) is advancing its ECLIPSE phase 3 program for tobevibart + elebsiran in Hepatitis Delta Virus, with topline data from all 3 studies expected Q1 2027. Company's dual-masked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback